

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	ADAM9; ADAM10; amyloid precursor protein (APP)	Cell culture studies suggest inhibiting the metalloproteinase ADAM9 could help treat AD by increasing ADAM10-mediated cleavage of APP. In APP-overexpressing neuroblastoma cells, an ADAM9-inhibiting peptide decreased ADAM10 cleavage and thus increased ADAM10-mediated APP cleavage compared with vehicle. Next steps include developing small molecule inhibitors of ADAM9 and testing ADAM9 inhibition in a mouse model of AD.	Unpatented; licensing status unavailable	Moss, M.L. <i>et al. J. Biol. Chem.</i> ; published online Sept. 28, 2011; doi:10.1074/jbc.M111.280495 Contact: Jörg W. Bartsch, University Hospital Marburg, Marburg, Germany e-mail: jbartsch@med.uni-marburg.de
<p><i>SciBX</i> 4(43); doi:10.1038/scibx.2011.1215 Published online Nov. 3, 2011</p>				